Very exciting news for advanced Parkinson's disease patients. With all the caveats associated with a 12-patient open-label study, the...

"The threat of the Inflation Reduction Act is so severe that Merck has fielded questions about whether it would choose to delay the...

Pretty exciting news for the neurodegeneration field for a PROTAC leader like Arvinas to jump in, providing another modality tool. For a...

Am I totally crazy to think this way? Wegovy cut the risk of major cardiovascular adverse events by 20% after 5 years and it's annual...